CD276 and head and neck squamous cell carcinoma: However, the relationship between the B7‐H3 expression and clinical features in patients with HNSCC remains unclear, and preclinical evidence revealing the antitumour immune response of B7‐H3 especially in immature myeloid cells is still uncertain.